Variations in radioiodine ablation: decision-making after total thyroidectomy

  • O. MaasEmail author
  • F. Forrer
  • M. Maas
  • C. M. Panje
  • J. Blautzik
  • M. Brühlmeier
  • I. Engel-Bicik
  • L. Giovanella
  • A. Haldemann
  • M. E. Kamel
  • S. Kneifel
  • C. Rottenburger
  • N. Schaefer
  • M. A. Walter
  • S. Weidner
  • P. M. Putora
Original Article
Part of the following topical collections:
  1. Oncology – Head and Neck



The role of radioiodine treatment following total thyroidectomy for differentiated thyroid cancer is changing. The last major revision of the American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer in 2015 changed treatment recommendations dramatically in comparison with the European Association of Nuclear Medicine (EANM) 2008 guidelines. We hypothesised that there is marked variability between the different treatment regimens used today.


We analysed decision-making in all Swiss hospitals offering radioiodine treatment to map current practice within the community and identify consensus and discrepancies.

Results and Conclusion

We demonstrated that for low-risk DTC patients after thyroidectomy, some institutions offered only follow-up, while RIT with significant activities is recommended in others. For intermediate- and high-risk patients, radioiodine treatment is generally recommended. Dosing and treatment preparation (recombinant human thyroid stimulation hormone (rhTSH) vs. thyroid hormone withdrawal (THW)) vary significantly among centres.


Radioiodine Thyroidectomy Treatment Decision Making 



The project was funded by a non-profit grant by Krebsliga Beider Basel as mentioned in the submission portal.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This survey analyses the participating centres for their treatment strategies. This information is derived directly from the clinical experts; individual patient data was not accessed.


  1. 1.
    Haugen BR, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRefGoogle Scholar
  2. 2.
    Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006;94(8):692–700.CrossRefGoogle Scholar
  3. 3.
    Hay ID, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008;144(6):980–8.CrossRefGoogle Scholar
  4. 4.
    Gerstein HC, et al. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89(8):3668–76.CrossRefGoogle Scholar
  5. 5.
    Sacks W, et al. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20(11):1235–45.CrossRefGoogle Scholar
  6. 6.
    Dalac A, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab. 2012;97(5):1526–35.CrossRefGoogle Scholar
  7. 7.
    Schmidt M, et al. A matter of controversy: is radioiodine therapy favorable in differentiated thyroid carcinoma? J Nucl Med. 2018;59(8):1195–201.CrossRefGoogle Scholar
  8. 8.
    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164–7.CrossRefGoogle Scholar
  9. 9.
    Hundsberger T, et al. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes—the Pompe disease burden scale. J Neurol. 2019.Google Scholar
  10. 10.
    Zumstein V, et al. Surgical management of urolithiasis - a systematic analysis of available guidelines. BMC Urol. 2018;18(1):25.CrossRefGoogle Scholar
  11. 11.
    Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? Cancer. 2017;123(3):372–81.CrossRefGoogle Scholar
  12. 12.
    Luster M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941.CrossRefGoogle Scholar
  13. 13.
    Verburg FA, et al. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43(6):1001–5.CrossRefGoogle Scholar
  14. 14.
    Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993. 114;(6):1050–7.Google Scholar
  15. 15.
    Hay ID, et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102(6):1088–95.PubMedGoogle Scholar
  16. 16.
    Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104(6):947–53.CrossRefGoogle Scholar
  17. 17.
    D’Avanzo A, et al. Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid. 2004;14(6):453–8.CrossRefGoogle Scholar
  18. 18.
    Putora PM, Oldenburg J. Swarm-based medicine. J Med Internet Res. 2013;15(9):e207.CrossRefGoogle Scholar
  19. 19.
    Glatzer M, et al. Decision-making criteria in oncology. Oncology. 2018;1–9.Google Scholar
  20. 20.
    Panje CM, et al. Applied swarm-based medicine: collecting decision trees for patterns of algorithms analysis. BMC Med Res Methodol. 2017;17(1):123.CrossRefGoogle Scholar
  21. 21.
    Steffen T, et al. Diagnostic nodes of patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy among colorectal cancer patients: a Swiss National Multicenter Survey. Clin Colorectal Cancer. 2019.Google Scholar
  22. 22.
    Rothermundt C, et al. Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma—analysis using diagnostic nodes. Oncologist. 2015;20(9):1028–35.CrossRefGoogle Scholar
  23. 23.
    Hundsberger T, et al. Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. J Neuro-Oncol. 2016;126(1):175–83.CrossRefGoogle Scholar
  24. 24.
    Panje CM, et al. Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: a survey on patterns of practice. Strahlenther Onkol. 2015;191(10):778–86.CrossRefGoogle Scholar
  25. 25.
    Putora PM, et al. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: selection of patients amongst European IASLC and ESTRO experts. Radiother Oncol. 2019;135:74–7.CrossRefGoogle Scholar
  26. 26.
    Putora PM, et al. Objective consensus from decision trees. Radiat Oncol. 2014;9:270.CrossRefGoogle Scholar
  27. 27.
    Nikiforov YE, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2(8):1023–9.CrossRefGoogle Scholar
  28. 28.
    Tuttle RM, et al. Controversies, consensus, and collaboration in the use of (131)I therapy in differentiated thyroid Cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29(4):461–70.CrossRefGoogle Scholar
  29. 29.
    Dietlein M, et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4. Nuklearmedizin. 2016;55(3):77–89.CrossRefGoogle Scholar
  30. 30.
    Tuttle RM. Controversial issues in thyroid cancer management. J Nucl Med. 2018;59(8):1187–94.CrossRefGoogle Scholar
  31. 31.
    (NCCN), N.C.C.N., Thyroid carcinoma, in Thyroid Carcinoma (Version 2.2018). 2018.Google Scholar
  32. 32.
    Vuong HG, et al. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-a meta-analysis. Clin Endocrinol. 2017;87(5):411–7.CrossRefGoogle Scholar
  33. 33.
    Zulewski H, et al. Multidisciplinary approach for risk-oriented treatment of low-risk papillary thyroid cancer in Switzerland. Swiss Med Wkly. 2019;149:w14700.PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • O. Maas
    • 1
    Email author
  • F. Forrer
    • 1
  • M. Maas
    • 1
  • C. M. Panje
    • 2
  • J. Blautzik
    • 3
  • M. Brühlmeier
    • 4
  • I. Engel-Bicik
    • 5
  • L. Giovanella
    • 6
  • A. Haldemann
    • 7
  • M. E. Kamel
    • 8
  • S. Kneifel
    • 9
  • C. Rottenburger
    • 10
  • N. Schaefer
    • 11
  • M. A. Walter
    • 12
  • S. Weidner
    • 13
  • P. M. Putora
    • 2
    • 14
  1. 1.Department of Radiology and Nuclear MedicineKantonsspital St. GallenSt. GallenSwitzerland
  2. 2.Department of Radiation OncologyKantonsspital St. GallenSt. GallenSwitzerland
  3. 3.Department of Radiology and Nuclear MedicineHislanden Klinik St. AnnaLuzernSwitzerland
  4. 4.Nuclear Medicine and PET-CentreKantonsspital AarauAarauSwitzerland
  5. 5.Department of Nuclear MedicineUniversity Hospital ZurichZurichSwitzerland
  6. 6.Department of Nuclear Medicine and PET-CentreRegional Hospital Lugano and BellinzonaBellinzonaSwitzerland
  7. 7.Department of Radiology and Nuclear MedicineStadtspital TriemliZurichSwitzerland
  8. 8.Department of Nuclear MedicineHôpital du ValaisSionSwitzerland
  9. 9.Department of Nuclear MedicineCantonal Hospital Graubünden ChurChurSwitzerland
  10. 10.Department of Radiology and Nuclear MedicineUniversity Hospital BaselBaselSwitzerland
  11. 11.Department of Nuclear MedicineUniversity Hospital LausanneLausanneSwitzerland
  12. 12.Department of Nuclear MedicineUniversity Hospital GenevaGenevaSwitzerland
  13. 13.Department of Nuclear MedicineInselspital BernBernSwitzerland
  14. 14.Department of Radiation OncologyUniversity of BernBernSwitzerland

Personalised recommendations